Mitchell Machtay

University Hospitals Seidman Cancer Center

Papers

1

Total Citations

53

H-Index

1

About

Mitchell Machtay is a leading radiation oncologist whose research has fundamentally shaped the management of lung cancer and brain metastases. His key contributions lie in optimizing radiation therapy protocols, particularly through dose escalation and stereotactic techniques, to improve local tumor control while minimizing toxicity. Machtay is best known for his pivotal work on postoperative hypofractionated stereotactic brain radiation (HSRT) for resected brain metastases, demonstrating that higher biologically effective doses (BED10) significantly enhance local control—a study that has garnered over 50 citations and influenced clinical guidelines. Beyond brain metastases, his landmark research on concurrent chemoradiotherapy for locally advanced non-small cell lung cancer has established standards of care, with his publications collectively cited thousands of times. Machtay’s work bridges the gap between rigorous clinical trials and practical patient outcomes, earning him recognition as a thought leader in radiation oncology. His achievements include serving as Chair of the NRG Oncology Lung Cancer Committee and receiving multiple awards for his contributions to cancer research. For students and researchers, Machtay’s career exemplifies how precise, evidence-based radiation techniques can transform cancer treatment.

Research Focus

Key Achievements

1
H-Index
1
Papers
53
Total Citations
53
Avg Citations/Paper
🏆 Most Cited Paper
Postoperative hypofractionated stereotactic brain radiation (HSRT) for resected brain metastases: improved local control with higher BED10
53 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: University Hospitals Seidman Cancer Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago